The Patent Finder

Watson Pharmaceuticals, Inc.

Also on record
Records under this name other than the patents Watson Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Watson Pharmaceuticals, Inc.

PatentTitleStatus Expires Confidence
US 7,959,946Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,084,058Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Term ended
Term ended Aug 26, 2026 · From the USPTO record
Term endedTerm ended Aug 26, 2026From the USPTO record
US 7,785,627Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Term ended Jul 31, 2026 · From the USPTO record
Term endedTerm ended Jul 31, 2026From the USPTO record
US 9,060,941Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Ended no later than Mar 11, 2025 · Low confidence
Term endedEnded no later than Mar 11, 2025Low confidence
US 7,303,763Compositions for conjugated estrogens and associated methods
Formerly held
Term ended
Term ended Apr 6, 2024 · From the USPTO record
Term endedTerm ended Apr 6, 2024From the USPTO record
US 8,470,368Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Term ended Nov 1, 2023 · From the USPTO record
Term endedTerm ended Nov 1, 2023From the USPTO record
US 8,309,125Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Ended no later than Sep 19, 2023 · From the USPTO record
Term endedEnded no later than Sep 19, 2023From the USPTO record
US 8,668,931Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Ended no later than Sep 19, 2023 · From the USPTO record
Term endedEnded no later than Sep 19, 2023From the USPTO record
US 8,551,516Administration of non-oral androgenic steroids to women
Formerly held
Term ended
Term ended Aug 31, 2022 · From the USPTO record
Term endedTerm ended Aug 31, 2022From the USPTO record
US 6,630,166Compositions for conjugated estrogens and associated methods
Formerly held
Term ended
Term ended Feb 12, 2022 · From the USPTO record
Term endedTerm ended Feb 12, 2022From the USPTO record
10 of 60 patents shown.
Pro members see all 60.
Pro members: see all 60 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited